聚乙二醇化
化学
纳米载体
脂质体
体内
药代动力学
药理学
聚乙二醇
体外
药物输送
红细胞
生物物理学
生物化学
医学
生物技术
有机化学
生物
作者
Patrick M. Glassman,Carlos H. Villa,Oscar A. Marcos‐Contreras,Elizabeth D. Hood,Landis R. Walsh,Colin F. Greineder,Jacob W. Myerson,Tea Shuvaeva,Laura N. Puentes,Nagarajan Kandasamy,Don L. Siegel,Vladimir R. Muzykantov
标识
DOI:10.1021/acs.bioconjchem.2c00196
摘要
Engineering drug delivery systems for prolonged pharmacokinetics (PK) has been an ongoing pursuit for nearly 50 years. The gold standard for PK enhancement is the coating of nanoparticles with polymers, namely polyethylene glycol (PEGylation), which has been applied in several clinically used products. In the present work, we utilize the longest circulating and most abundant component of blood─the erythrocyte─to improve the PK behavior of liposomes. Antibody-mediated coupling of liposomes to erythrocytes was tested in vitro to identify a loading dose that did not adversely impact the carrier cells. Injection of erythrocyte targeting liposomes into mice resulted in a ∼2-fold improvement in the area under the blood concentration versus time profile versus PEGylated liposomes and a redistribution from the plasma into the cellular fraction of blood. These results suggest that in vivo targeting of erythrocytes is a viable strategy to improve liposome PK relative to current, clinically viable strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI